Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px
Document › Details

Macrophage Pharma Ltd.. (5/11/17). "Press Release: Macrophage Pharma Appoints Development Director. Dr Joanne Bedwell-Garner Joins Management Team".

Organisations Organisation Macrophage Pharma Ltd. (MPL)
  Organisation 2 BTG plc (LSE: BTG)
  Group BTG (Group)
Products Product ESM™ technology (Esterase Sensitive Motif technology)
  Product 2 small-molecule cancer drug
Index term Index term Macrophage Pharma–SEVERAL: investment, 201701 financing round Series A £9m led by CRT Pioneer Fund + incl Novo Seeds + Aglaia
Person Person Vile, Hollie (Hume Brophy 201309– Account Director before M:Communications)
     


Macrophage Pharma Limited (‘MPL’) the immuno-oncology development company, announced today that it has appointed Dr Joanne Bedwell-Garner as Development Director. Dr Bedwell-Garner will be responsible for advancing the clinical development of Macrophage Pharma’s lead programme, MPL-5821. This announcement follows the recent £9 million Series A financing, which was led by CRT Pioneer Fund (CPF) and two new specialist investors, Novo A/S and Aglaia Biomedical Ventures BV.

Dr Bedwell-Garner brings over 25 years’ experience in the pharmaceutical sector, having held numerous senior Research and Development roles at companies including BTG, where she was Vice President of Non-Clinical Development and was responsible for non-clinical evaluation and translation into the clinic. Prior to this she held senior roles at Protherics, Emergent BioSolutions and Microscience. Dr Bedwell-Garner has a successful track record in taking greater than 15 pre-clinical candidates into clinical development; particularly in the areas of oncology, inflammation, cardiovascular and infectious disease. She obtained a PhD in oncology from University of London.

Dr Joanne Bedwell-Garner, newly appointed Development Director, said: “I am excited to join Macrophage Pharma’s highly experienced team to maximise the full therapeutic potential of the ESM technology in immuno-oncology.”

Macrophage Pharma’s ESM technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner, activating the body’s natural immune system to fight cancer. The platform has the ability to provide next-generation immunotherapies for a number of different cancers.

The Company’s lead p38MAPi programme is focused on a novel macrophage-targeting p38 MAPK inhibitor. Clinical trials are scheduled to start in 2018. The Company is also developing discovery stage programmes centred on a number of proprietary, candidate compounds.

Macrophage Pharm will be presenting at Bio€quity Europe 2017 on Monday 22nd May at 4.20pm in the Next Wave company session.


About Macrophage Pharma Limited

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses.

Its proprietary Esterase Motif Technology (ESM) platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner, activating the body’s natural immune system to fight cancer. The platform has the ability to provide next-generation immunotherapies for a number of different cancers.

Founded by the CRT Pioneer Fund (CPF), the Company recently raised £9 million in a Series A financing round, led by CPF and two new specialist investors, Novo A/S and Aglaia Biomedical Ventures BV.

Macrophage Pharma’s strategy is to complete the preclinical development of its lead development candidate, a p38 MAP kinase inhibitor, and advance two additional discovery candidates into pre-clinical development.

The company’s management team, led by Dr Steven Powell, Chief Executive Officer, has a track record of success in the pharma industry ranging from early discovery to commercialisation. The Scientific Advisory Board is comprised of world-leading immunologists and cancer researchers who will help shape the future development of the company’s unique approach in immuno-oncology.

For more information, please visit the company website: www.macrophagepharma.com


Media Contact:

Macrophage Pharma
Steven Powell, Chief Executive Officer
Email: enquiries@macrophagepharma.com

Hollie Vile
Email: hollie@macrophagepharma.com
Tel: +44-(0)-7729-362-590
Posted on 11th May 2017

   
Record changed: 2017-08-27

Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 600x60px

More documents for Macrophage Pharma Ltd. (MPL)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 22 Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 41 Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px